Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program
Vanda Pharmaceuticals' Phase III Study 3201 of VQW-765 in adults with social anxiety disorder failed to meet its primary endpoint of distress reduction (SUDS) in female participants during the Trier Social Stress Test performance phase (p=0.8899). The 546-patient, 30-site randomized study also missed the key secondary endpoint in the full male and female population (p=0.6605), failing to confirm earlier positive Phase II findings.
Key figures
- Drug Name
- VQW-765
- Phase Of Trial
- Phase 3
- Clinical sites
- approximately 30
- Program status
- on hold pending further analysis of full dataset
- Patients randomized
- 546
- Key secondary pvalue
- 0.6605
- Primary endpoint pvalue
- 0.8899
- Primary endpoint ls mean difference
- -0.4 (95% CI -5.32, 4.62)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.